Mealey's (June 17, 2016, 1:46 PM EDT) -- NEWARK, N.J. — A shareholder filed a securities class action complaint in New Jersey federal court on June 9, alleging that a pharmaceutical company and certain of its executive officers misrepresented the clinical test results for a cancer treatment drug the company was developing in violation of federal securities laws (Jessica Fergus v. Immunomedics Inc., et al., No. 16-3335, D. N.J.)....